Dogwood Therapeutics, Inc. (NASDAQ:DWTX – Free Report) – Research analysts at Zacks Small Cap decreased their FY2024 earnings per share estimates for Dogwood Therapeutics in a research report issued on Monday, November 11th. Zacks Small Cap analyst D. Bautz now anticipates that the company will earn ($6.43) per share for the year, down from their prior estimate of ($5.71). The consensus estimate for Dogwood Therapeutics’ current full-year earnings is ($5.84) per share.
Dogwood Therapeutics Stock Down 14.2 %
NASDAQ:DWTX opened at $2.97 on Wednesday. Dogwood Therapeutics has a 12-month low of $2.50 and a 12-month high of $23.50. The firm has a market capitalization of $3.95 million, a P/E ratio of -0.50 and a beta of 1.57.
About Dogwood Therapeutics
Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company’s lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.
Featured Stories
- Five stocks we like better than Dogwood Therapeutics
- What is a Low P/E Ratio and What Does it Tell Investors?
- Rocket Lab is the Right Stock for the Right Time
- What is a support level?
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- Profitably Trade Stocks at 52-Week Highs
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for Dogwood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dogwood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
